2956 related articles for article (PubMed ID: 24779310)
1. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
Hitzler WE
Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
[TBL] [Abstract][Full Text] [Related]
2. [Risk Assessment of Single-Donor (Apheresis) Platelet Concentrates and Pooled Whole-Blood-Derived Platelet Concentrates].
Hitzler W; Hutschenreuter G; Wartensleben H;
Clin Lab; 2015; 61(7):869-75. PubMed ID: 26299092
[TBL] [Abstract][Full Text] [Related]
3. Implications of a switch to a 100% apheresis platelet supply for patients and for blood donors: a risk benefit analysis.
Thiele T; Alt-Mayer T; Greinacher A; Bux J
Vox Sang; 2016 Nov; 111(4):350-356. PubMed ID: 27432635
[TBL] [Abstract][Full Text] [Related]
4. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
5. Consistency and proportionality in policy decision-making in blood safety: the case for an all-apheresis platelet supply in Germany.
Vamvakas EC; Hitzler WE
Clin Lab; 2013; 59(1-2):1-22. PubMed ID: 23505902
[TBL] [Abstract][Full Text] [Related]
6. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
7. Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany.
an der Heiden M; Ritter S; Hamouda O; Offergeld R
Vox Sang; 2015 Feb; 108(2):123-30. PubMed ID: 25335096
[TBL] [Abstract][Full Text] [Related]
8. [Report on notifications pursuant to Section 21 German Transfusion Act for 2007].
Henseler O; Heiden M; Haschberger B; Hesse J; Seitz R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jul; 52(7):715-31. PubMed ID: 19572110
[TBL] [Abstract][Full Text] [Related]
9. Namibia's transition from whole blood-derived pooled platelets to single-donor apheresis platelet collections.
Pitman JP; Basavaraju SV; Shiraishi RW; Wilkinson R; von Finckenstein B; Lowrance DW; Marfin AA; Postma M; Mataranyika M; Smit Sibinga CT
Transfusion; 2015 Jul; 55(7):1685-92. PubMed ID: 25727921
[TBL] [Abstract][Full Text] [Related]
10. A general change of the platelet transfusion policy from apheresis platelet concentrates to pooled platelet concentrates is associated with a sharp increase in donor exposure and infection rates.
Heuft HG; Mende W; Blasczyk R
Transfus Med Hemother; 2008 Apr; 35(2):106-13. PubMed ID: 21512637
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
[TBL] [Abstract][Full Text] [Related]
12. Platelet concentrates, from whole blood or collected by apheresis?
van der Meer PF
Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.
Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF
Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766
[TBL] [Abstract][Full Text] [Related]
14. Overview: diagnostic tests for viral infections transmitted by blood.
Holland PV
Nucl Med Biol; 1994 Apr; 21(3):407-17. PubMed ID: 9234305
[TBL] [Abstract][Full Text] [Related]
15. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
Lozano ML; Rivera J; Vicente V
Med Clin (Barc); 2012 May; 138(12):528-33. PubMed ID: 21807386
[TBL] [Abstract][Full Text] [Related]
16. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
Vamvakas EC
Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
[TBL] [Abstract][Full Text] [Related]
17. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
[TBL] [Abstract][Full Text] [Related]
18. Storage and transfusion of infected autologous blood or components: a survey of North American laboratories.
Shulman IA; Osby M
Arch Pathol Lab Med; 2005 Aug; 129(8):981-3. PubMed ID: 16048409
[TBL] [Abstract][Full Text] [Related]
19. Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system.
Abedi MR; Doverud AC
J Vis Exp; 2012 Dec; (70):e4414. PubMed ID: 23242463
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
